Equities

Sensus Healthcare Inc

Sensus Healthcare Inc

Actions
  • Price (EUR)5.85
  • Today's Change0.300 / 5.41%
  • Shares traded-1.00
  • 1 Year change+120.09%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.

  • Revenue in USD (TTM)31.66m
  • Net income in USD4.65m
  • Incorporated2010
  • Employees35.00
  • Location
    Sensus Healthcare Inc851 Broken Sound Pkwy NW Ste 215BOCA RATON 33487-3635United StatesUSA
  • Phone+1 (561) 922-5808
  • Fax+1 (561) 948-2071
  • Websitehttps://sensushealthcare.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.